FDA Oncology Announcements

FGFR inhibitor × Clear all

7 Announcements

FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma

Trial: THOR
Drug: Balversa (erdafitinib) · FGFR inhibitor
Condition: Genitourinary

FDA grants accelerated approval to futibatinib for cholangiocarcinoma

Drug: Lytgobi (futibatinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement

Drug: Pemazyre (pemigatinib) · FGFR inhibitor
Conditions: LymphoidMyeloid

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma

Drug: Truseltiq (infigratinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion

Drug: PEMAZYRE (pemigatinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion

Drug: PEMAZYRE (pemigatinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

Drug: BALVERSA (erdafitinib) · FGFR inhibitor
Condition: Genitourinary